✉news BusinessLabor first seen 7 d ago, last 6 d ago, peak #4

Zealand Pharma signs AI obesity drug deal worth up to $1.2 billion

Original: Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion

Danish biotech Zealand Pharma has struck a deal with AI drug discovery company Generate (Generate Biomedicines) to develop obesity treatments, in an agreement worth up to $1.2 billion. The tie-up pairs Zealand's peptide expertise with Generate's generative AI platform, as big pharma and biotech race to find the next generation of weight-loss drugs beyond GLP-1 blockbusters like Wegovy and Zepbound.

Why now: Obesity drug development is one of the hottest areas in pharma, and the use of AI to design new medicines plus the large deal value are drawing attention.

Zealand PharmaGenerate Biomedicines

Open on news →

Evidence

• Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion · Reuters

API: https://socialmediatrends-api.osmike.com/v1/trends/2154728